knowledge -WSS

knowledge

author：knowledge 2025-10-04 12:00:21 Page View：5

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck
Next article： Hollywood unions extend contract negotiations for actors

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

Bernie Sanders is gearing up to subpoena pharma CEOs

Sen.BernieSandersisaskinghiscolleaguestoissueasubpoenaoftwopharmaceuticalcompanyCEOs.KevinDietsch/Ge

Alkermes shareholders re

MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

10 reasons why health care startups fail

AdobeInourrolesatMedTechInnovator,aglobalacceleratorformedtechstartups,we’veworkedwiththousandsofear

knowledge

leisure time

focus

10 reasons why health care startups fail